Strides Pharma Science reported a consolidated net profit of ₹1.6 billion for Q1FY27, compared to ₹1 billion in the same quarter of the previous year, reflecting a significant year-on-year improvement in bottom-line performance. The results were discussed during the company's earnings conference call held on July 31, 2026, at 5:00 PM IST, where management provided insights into the quarterly financial outcomes and operational developments.

Q1FY27 Financial Highlights

The latest quarterly results underscore a notable improvement in profitability for Strides Pharma Science on a year-on-year basis. The following table summarises the key financial metric reported:

Earnings Conference Call Details

The Q1FY27 results were presented to investors and analysts through a scheduled earnings conference call. The management team led the discussion, offering insights into operational metrics and financial outcomes for the period. Key executives who participated in the call included:

• Badree Komandur, Managing Director & Group CEO
• Vikesh Kumar, Group CFO

The invitation for the call was issued by Manjula Ramamurthy, Company Secretary & Compliance Officer, on July 24, 2026.

Participants joined the session via webcast or through dial-in numbers available for India, the USA, the UK, Singapore, and Hong Kong. Detailed joining instructions and the formal invitation are available on the company's website at www.strides.com .

Investor Significance

This quarterly earnings disclosure is a standard regulatory practice for listed entities in India, ensuring transparency in financial reporting. The year-on-year improvement in consolidated net profit provides stakeholders with a direct measure of the company's financial progress, with management available to address queries on revenue drivers, margin trends, and other material developments from the Q1FY27 period.

Strides Pharma Science Limited has convened its 35th Annual General Meeting (AGM) on Friday, August 14, 2026, at 12:15 hrs IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM), in compliance with circulars issued by the Ministry of Corporate Affairs (MCA) and the Securities and Exchange Board of India (SEBI). The company has fixed Friday, July 31, 2026 as the record date to determine shareholder eligibility for a final dividend of ₹5 per equity share — representing 50% of the face value of ₹10 per share — for the financial year ended March 31, 2026. The dividend, recommended by the Board of Directors on May 18, 2026, is subject to shareholder approval at the AGM. If approved, the payout will be made within 30 days from the date of declaration through permissible electronic modes, after applicable tax deductions at source.

Key AGM Event Dates

The following table summarises the critical dates and details relating to the 35th AGM:

Ordinary and Special Business at the AGM

The AGM agenda covers both ordinary and special business. Under ordinary business, shareholders will consider adoption of audited financial statements for FY 2025-26, declaration of the final dividend, and the re-appointment of Mr. Arun Kumar (DIN: 00084845) — Founder, Non-Executive Director and Chairperson — who retires by rotation and offers himself for re-appointment. Under special business, shareholders will vote on the following key proposals:

Board Transition and Director Profiles

Aditya Arun Kumar, aged approximately 37 years, transitioned from his role as Executive Director – Business Development to a Non-Executive Director effective June 1, 2026, in line with the promoters' stated objective of professionalising management. He holds a bachelor's degree in biomedical sciences from Newcastle University and a Master of Research in Biophysics from King's College, London, and has over 13 years of experience in the pharmaceutical industry. As at the date of the AGM Notice, Aditya holds 58,422 equity shares (~0.06% of paid-up capital).

Ram, aged approximately 53 years, has been associated with the Strides Group since 2007 and was appointed Chief Operating Officer (COO) effective March 1, 2024. He holds a post-graduate degree in Pharmaceutical Chemistry from BITS Pilani and brings over 30 years of pharmaceutical industry experience. His proposed remuneration as Executive Director includes a fixed pay of ₹3.60 crores per annum and variable pay of ₹1.44 crores per annum, with long-term incentives linked to manufacturing, supply chain leadership, ESG integration, and digital transformation goals over his three-year tenure. As at the date of the AGM Notice, Ram holds 44,000 equity shares (~0.048% of paid-up capital) and 20,000 stock options exercisable during FY27 and FY28.

FY 2025-26 Financial Highlights

The company reported strong consolidated financial performance for FY 2025-26, as summarised below:

The total dividend payout, if approved, would amount to approximately ₹461 million, representing a payout ratio of 25% on a standalone basis and 8% on a consolidated basis. Net debt stood at ₹14,365 million as at March 31, 2026, with the net debt-to-equity ratio improving to 0.46x from 0.59x in FY25. Return on Capital Employed (ROCE) improved to 15.76% in FY26 from 14.86% in FY25.

E-voting and Participation

Shareholders whose names appear in the Register of Members as on the cut-off date of August 7, 2026 are entitled to vote on the resolutions. Remote e-voting is available via KFin Technologies Limited at https://evoting.kfintech.com/ . Shareholders may also attend the AGM through VC/OAVM using the same credentials. Speaker registration for the AGM is open from August 10, 2026 (09:00 hrs IST) to August 12, 2026 (17:00 hrs IST). The scrutinizer for the AGM is Mr. Gigi Joseph K J, Practicing Company Secretary (ICSI Membership No. F6483), and results will be declared on or before August 18, 2026. The AGM Notice and Annual Report for FY 2025-26 are available on the company's website at www.strides.com and on the websites of BSE Limited and National Stock Exchange of India Limited.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE939A01011/285e0924a57c4161.pdf